SCHEMBL235440

SCHEMBL235440

NC(CCC(=O)NC(CS)C(=O)N(CC(=O)O)N=O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.56
GSTK1 Q9Y2Q3 1/20 0.56
GLO1 Q04760 1/20 0.42
NOD1 Q9Y239 9/20 0.41
FOLH1 Q04609 3/20 0.40
GRM8 O00222 1/20 0.38
GRM6 O15303 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GSR P00390 1/20 0.38
CYP1A2 P05177 1/20 0.38
GRIK1 P39086 1/20 0.38
GRM5 P41594 1/20 0.38
GRIA1 P42261 1/20 0.38
GRIA2 P42262 1/20 0.38
GRIA3 P42263 1/20 0.38
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
GRIA4 P48058 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15668617 0.98 PTGS1 (0.54) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL10276937 0.86 PTGS1 (0.52) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL246687 0.85 PTGS1 (0.46) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL5463061 0.84 PTGS1 (0.61) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL1332934 0.84 PTGS1 (0.61) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL365796 0.84 PTGS1 (0.57) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL316091 0.83 PTGS1 (0.60) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL19549046 0.83 PTGS1 (0.60) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL4657010 0.82 PTGS1 (0.56) PTGS1GSTK1GLO1NOD1FOLH1
SCHEMBL993262 0.82 PTGS1 (0.59) PTGS1GSTK1GLO1NOD1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 897 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288607-A1 METHODS FOR TREATING SEXUAL DYSFUNCTION ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME (PCOS) OR WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) Institut National de la Santé et de la Recherche Médicale (FR) 2025-09-18 US claimed
EP-4522146-A1 METHODS FOR TREATING SEXUAL DYSFUNCTION ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME (PCOS) OR WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) Institut National de la Santé et de la Recherche Médicale (FR) 2025-03-19 EP claimed
CN-119055582-A Quick-dissolving microneedle patch capable of improving androgenetic alopecia and preparation method and application thereof 西北大学 2024-12-03 CN claimed
WO-2024151479-A1 CONTAINERS AND METHODS FOR NITRIC OXIDE STERILIZATION STERILE STATE, LLC (US) 2024-07-18 WO claimed
EP-4384272-A1 ANTIBACTERIAL PORPHYRIN NANOPARTICLES AND METHODS FOR MAKING AND USING THE SAME University of Georgia Research Foundation, Inc. (US) 2024-06-19 EP claimed
CN-118021752-A Mitochondrial targeting immunostimulation nano-drug capable of crossing blood brain barrier 山东大学齐鲁医院 2024-05-14 CN claimed
US-20240091552-A1 SYSTEMS AND METHODS FOR PHOTOTHERAPEUTIC MODULATION OF NITRIC OXIDE FP VENTURE DEBT I BETA LTD (CY) 2024-03-21 US claimed
WO-2024052927-A1 NOVEL POLYMERIC FILM AND PAPER BASED PACKAGING SYSTEM TO DECELERATE SENESCENCE OF CLIMACTERIC AND NON-CLIMACTERIC HORTICULTURE PRODUCE ORIENT PRESS LIMITED (IN) 2024-03-14 WO claimed
US-20240041036-A1 BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS FERTIS INDIA PVT. LTD. (IN) 2024-02-08 US claimed
EP-4304717-A1 USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY Chronic Airway Therapeutics Limited (AU) 2024-01-17 EP claimed
WO-2001085013-A2 INFRARED THERMOGRAPHY AND METHODS OF USE NITROMED, INC. (US) 2001-11-15 WO claimed
WO-2001070199-A1 MATRICES CONTAINING NITRIC OXIDE DONORS AND REDUCING AGENTS AND THEIR USE NOVOVASCULAR, INC. (US) 2001-09-27 WO claimed
US-20010012834-A1 Treating pulmonary disorders with gaseous agent causing repletion of GSNO DUKE UNIVERSITY (US) 2001-08-09 US claimed
WO-2001017596-A1 METHOD OF TREATING CARDIO PULMONARY DISEASES WITH NO GROUP COMPOUNDS DUKE UNIVERSITY (US) 2001-03-15 WO claimed
US-6159500-A Pharmaceutical preparations of glutathione and methods of administration thereof ANTIOXIDANT PHARMACEUTICALS CORPORATION (US) 2000-12-12 US claimed
EP-0957901-A1 PHARMACEUTICAL PREPARATIONS OF GLUTATHIONE AND METHODS OF ADMINISTRATION THEREOF Antioxidant Pharmaceuticals Corporation (US) 1999-11-24 EP claimed
EP-0914348-A1 POLYMERS FOR DELIVERING NITRIC OXIDE IN VIVO DUKE UNIVERSITY MEDICAL CENTER (US) 1999-05-12 EP claimed
WO-1998029101-A1 PHARMACEUTICAL PREPARATIONS OF GLUTATHIONE AND METHODS OF ADMINISTRATION THEREOF ANTIOXIDANT PHARMACEUTICALS CORPORATION (US) 1998-07-09 WO claimed
WO-1998005689-A1 POLYMERS FOR DELIVERING NITRIC OXIDE IN VIVO DUKE UNIVERSITY MEDICAL CENTER (US) 1998-02-12 WO claimed
US-5626738-A Methods for the separation and detection of nitrosothiols AMERICAN HEALTH FOUNDATION (US) 1997-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041036-A1 BIO PESTICIDAL COMPOSITION CONTAINS NOVEL NONANOATE ESTERS OF SUGARS AND SUGAR ALCOHOLS TO CONTROL LEPIDOPTERA, HEMIPTERA AND THYSANOPTERA INSECTS MGLL, ACHE, GMDS PTGS1 2668/4885GSTK1 1661/4885GLO1 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.